ATRC-101,Pembrolizumab
Atreca,merck
['solid tumor']
atreca presents data from ongoing phase 1b study of atrc-101 in patients with select advanced solid tumors during oral abstract session at the asco 2023 annual meeting - health stocks hub $bcel 
Real-Time News, Market Data, Insider Trades, and Stock Quotes for Biotech, Pharma, Medical, and Healthcare Stocks @ https://t.co/Oqp6BRBKy2